Immunic announces positive results from single and multiple ascending dose parts of its phase 1 clinical trial of imu-856 in healthy human subjects

– unblinded data revealed a favorable safety, tolerability and pharmacokinetic profile for imu‑856 in single and 14-day multiple dosing – – no maximum tolerated dose reached; investigated doses expected to exceed required therapeutic dosing of imu-856 – – third portion of phase 1 clinical trial in patients with celiac disease ongoing – – webcast to be held today, september 20, 2022, at 8:30 am et – new york , sept. 20, 2022 /prnewswire/ -- immunic, inc. (nasdaq: imux), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced positive unblinded safety, tolerability and pharmacokinetic (pk) results from part a (single ascending doses, sad) and part b (multiple ascending doses, mad) of its phase 1 clinical trial of imu-856 in healthy human subjects.
IMUX Ratings Summary
IMUX Quant Ranking